-
Je něco špatně v tomto záznamu ?
Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events
P. Burda, A. Hlavackova, V. Polivkova, N. Curik, A. Laznicka, J. Krizkova, J. Suttnar, P. Klener, KM. Polakova
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2012
Free Medical Journals
od 2012
PubMed Central
od 2012
Open Access Digital Library
od 2012-12-01
Open Access Digital Library
od 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2012
- MeSH
- chronická myeloidní leukemie * farmakoterapie metabolismus MeSH
- energetický metabolismus účinky léků MeSH
- imatinib mesylát * farmakologie škodlivé účinky MeSH
- inhibitory proteinkinas farmakologie škodlivé účinky MeSH
- karnitin * metabolismus farmakologie MeSH
- lidé MeSH
- mitochondrie metabolismus účinky léků MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- protinádorové látky škodlivé účinky farmakologie MeSH
- rodina nosičů rozpuštěných látek 22, člen 5 * metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVE: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with imatinib report skeletomuscular adverse events affecting their quality of life. OCTN2 membrane transporter is involved in imatinib transportation into the cells. At the same time, the crucial physiological role of OCTN2 is cellular uptake of carnitine which is an essential co-factor for the mitochondrial β-oxidation pathway. This work investigates the impact of imatinib treatment on carnitine intake and energy metabolism of muscle cells. METHODS: HTB-153 (human rhabdomyosarcoma) cell line and KCL-22 (CML cell line) were used to study the impact of imatinib treatment on intracellular levels of carnitine and vice versa. The energy metabolism changes in cells treated by imatinib were quantified and compared to changes in cells exposed to highly specific OCTN2 inhibitor vinorelbine. Mouse models were used to test whether in vitro observations are also achieved in vivo in thigh muscle tissue. The analytes of interest were quantified using a Prominence HPLC system coupled with a tandem mass spectrometer. RESULTS: This work showed that through the carnitine-specific transporter OCTN2, imatinib and carnitine intake competed unequally and intracellular carnitine concentrations were significantly reduced. In contrast, carnitine preincubation did not influence imatinib cell intake or interfere with leukemia cell targeting. Blocking the intracellular supply of carnitine with imatinib significantly reduced the production of most Krebs cycle metabolites and ATP. However, subsequent carnitine supplementation rescued mitochondrial energy production. Due to specific inhibition of OCTN2 activity, the influx of carnitine was blocked and mitochondrial energy metabolism was impaired in muscle cells in vitro and in thigh muscle tissue in a mouse model. CONCLUSIONS: This preclinical experimental study revealed detrimental effect of imatinib on carnitine-mediated energy metabolism of muscle cells providing a possible molecular background of the frequently occurred side effects during imatinib therapy such as fatigue, muscle pain and cramps.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018751
- 003
- CZ-PrNML
- 005
- 20241024111344.0
- 007
- ta
- 008
- 241015e20240823gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.molmet.2024.102016 $2 doi
- 035 __
- $a (PubMed)39182842
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Burda, Pavel $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 245 10
- $a Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events / $c P. Burda, A. Hlavackova, V. Polivkova, N. Curik, A. Laznicka, J. Krizkova, J. Suttnar, P. Klener, KM. Polakova
- 520 9_
- $a OBJECTIVE: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with imatinib report skeletomuscular adverse events affecting their quality of life. OCTN2 membrane transporter is involved in imatinib transportation into the cells. At the same time, the crucial physiological role of OCTN2 is cellular uptake of carnitine which is an essential co-factor for the mitochondrial β-oxidation pathway. This work investigates the impact of imatinib treatment on carnitine intake and energy metabolism of muscle cells. METHODS: HTB-153 (human rhabdomyosarcoma) cell line and KCL-22 (CML cell line) were used to study the impact of imatinib treatment on intracellular levels of carnitine and vice versa. The energy metabolism changes in cells treated by imatinib were quantified and compared to changes in cells exposed to highly specific OCTN2 inhibitor vinorelbine. Mouse models were used to test whether in vitro observations are also achieved in vivo in thigh muscle tissue. The analytes of interest were quantified using a Prominence HPLC system coupled with a tandem mass spectrometer. RESULTS: This work showed that through the carnitine-specific transporter OCTN2, imatinib and carnitine intake competed unequally and intracellular carnitine concentrations were significantly reduced. In contrast, carnitine preincubation did not influence imatinib cell intake or interfere with leukemia cell targeting. Blocking the intracellular supply of carnitine with imatinib significantly reduced the production of most Krebs cycle metabolites and ATP. However, subsequent carnitine supplementation rescued mitochondrial energy production. Due to specific inhibition of OCTN2 activity, the influx of carnitine was blocked and mitochondrial energy metabolism was impaired in muscle cells in vitro and in thigh muscle tissue in a mouse model. CONCLUSIONS: This preclinical experimental study revealed detrimental effect of imatinib on carnitine-mediated energy metabolism of muscle cells providing a possible molecular background of the frequently occurred side effects during imatinib therapy such as fatigue, muscle pain and cramps.
- 650 12
- $a karnitin $x metabolismus $x farmakologie $7 D002331
- 650 12
- $a imatinib mesylát $x farmakologie $x škodlivé účinky $7 D000068877
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a myši $7 D051379
- 650 12
- $a chronická myeloidní leukemie $x farmakoterapie $x metabolismus $7 D015464
- 650 12
- $a rodina nosičů rozpuštěných látek 22, člen 5 $x metabolismus $7 D000074058
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a protinádorové látky $x škodlivé účinky $x farmakologie $7 D000970
- 650 _2
- $a energetický metabolismus $x účinky léků $7 D004734
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $x škodlivé účinky $7 D047428
- 650 _2
- $a mitochondrie $x metabolismus $x účinky léků $7 D008928
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hlavackova, Alzbeta $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Polivkova, Vendula $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Curik, Nikola $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Laznicka, Adam $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Krizkova, Jitka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Suttnar, Jiri $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Klener, Pavel $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; First Medical Department- Dept. of Hematology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a Polakova, Katerina Machova $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: Katerina.Machova@uhkt.cz
- 773 0_
- $w MED00190571 $t Molecular metabolism $x 2212-8778 $g Roč. 88 (20240823), s. 102016
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39182842 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111338 $b ABA008
- 999 __
- $a ok $b bmc $g 2201550 $s 1230724
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 88 $c - $d 102016 $e 20240823 $i 2212-8778 $m Molecular metabolism $n Mol Metab $x MED00190571
- LZP __
- $a Pubmed-20241015